Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia

Br J Haematol. 2019 Jul;186(1):184-188. doi: 10.1111/bjh.15791. Epub 2019 Feb 10.
No abstract available

Keywords: chronic lymphocytic leukaemia; genomic risk factors; ibrutinib; tumour debulking; tumour lysis syndrome risk.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Aged
  • Antineoplastic Agents / adverse effects*
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / complications
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Male
  • Middle Aged
  • Piperidines
  • Pyrazoles / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Tumor Burden / drug effects
  • Tumor Lysis Syndrome / etiology*
  • Tumor Lysis Syndrome / prevention & control

Substances

  • Antineoplastic Agents
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Adenine